Methods and compositions for the treatment of Sengers syndrome

Patent metadata

Field	Value
Publication number	US-11931397-B2
Application number	US-201917299681-A
Country	US
Kind code	B2
Filing date	Dec 5, 2019
Priority date	Dec 6, 2018
Publication date	Mar 19, 2024
Grant date	Mar 19, 2024

Abstract

The disclosure provides methods of preventing or treating Sengers syndrome in a mammalian subject, reducing risk factors associated with Sengers syndrome, and/or reducing the likelihood or severity of Sengers syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of AGK in subjects in need thereof.

First claim

What is claimed is:

1. A method for treating or preventing Sengers syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH 2 or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the subject displays reduced levels of acylglycerol kinase (AGK) expression compared to a normal control subject.

3. The method of claim 1 , wherein the peptide is administered daily for 6 weeks or more.

4. The method of claim 1 , wherein the peptide is administered daily for 12 weeks or more.

5. The method of claim 1 , wherein the subject has been diagnosed as having Sengers syndrome.

6. The method of claim 5 , wherein the Sengers syndrome comprises one or more of cataracts, hypertrophic cardiomyopathy, reduced cardiac function as assessed by ejection fraction, skeletal myopathy, exercise intolerance, lactic acidosis, neutropenia, tachydyspnea, nystagmus, eosinophilia, cervical meningocele, isolated Complex I deficiency, strabismus, hypotonia, hyporeflexia, delayed motor development, reduced AGK expression, reduced mitochondrial levels of glutamate carrier 1 (GC1), reduced mitochondrial levels of adenine nucleotide transporter type 1 (ANT1), reduced mitochondrial levels of adenine nucleotide transporter type 3 (ANT3), reduced mitochondrial levels of phosphate carrier (PiC), and reduced mitochondrial levels of translocase of the inner membrane 22 (TIM22) subunits (hTim22, Tim29, and hTim9).

7. The method of claim 1 , wherein the subject is human.

8. The method of claim 1 , wherein the peptide is administered orally, topically, systemically, intravenously, subcutaneously, intraocularly, intraperitoneally, or intramuscularly.

9. The method of claim 1 , further comprising separately, sequentially or simultaneously administering a cardiovascular agent to the subject.

10. The method of claim 9 , wherein the cardiovascular agent is selected from the group consisting of: a diuretic, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker or inhibitor, an angiotensin-receptor neprilysin inhibitor (ARNI), an I f channel blocker or inhibitor, a beta blocker, an aldosterone antagonist, a hydralazine and isosorbide dinitrate, a diuretic, and digoxin.

11. The method of claim 1 , wherein the pharmaceutically acceptable salt comprises acetate, hydrochloride or trifluoroacetate salt.

12. A method for increasing the expression of AGK in a mammalian subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH 2 or a pharmaceutically acceptable salt thereof.

13. The method of claim 12 , wherein the expression of AGK in the subject is about 2-5 fold less than the level of AGK expression in a normal control subject.

14. The method of claim 12 , wherein the peptide is administered daily for 6 weeks or more.

15. The method of claim 12 , wherein the peptide is administered daily for 12 weeks or more.

16. The method of claim 12 , wherein the subject has been diagnosed as having, is suspected of having, or is at risk of having Sengers syndrome.

17. The method of claim 16 , wherein the Sengers syndrome comprises one or more of cataracts, hypertrophic cardiomyopathy, reduced cardiac function as assessed by ejection fraction, skeletal myopathy, exercise intolerance, lactic acidosis, neutropenia, tachydyspnea, nystagmus, eosinophilia, cervical meningocele, isolated Complex I deficiency, strabismus, hypotonia, hyporeflexia, delayed motor development, reduced AGK expression, reduced mitochondrial levels of glutamate carrier 1 (GC1), reduced mitochondrial levels of adenine nucleotide transporter type 1 (ANT1), reduced mitochondrial levels of adenine nucleotide transporter type 3 (ANT3), reduced mitochondrial levels of phosphate carrier (PiC), and reduced mitochondrial levels of translocase of the inner membrane 22 (TIM22) subunits (hTim22, Tim29, and hTim9).

18. The method of claim 12 , wherein the subject is human.

19. The method of claim 12 , wherein the peptide is administered orally, topically, systemically, intravenously, subcutaneously, intraocularly, intraperitoneally, or intramuscularly.

20. The method of claim 12 , further comprising separately, sequentially or simultaneously administering a cardiovascular agent to the subject.

21. The method of claim 20 , wherein the cardiovascular agent is selected from the group consisting of: a diuretic, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker or inhibitor, an angiotensin-receptor neprilysin inhibitor (ARNI), an I f channel blocker or inhibitor, a beta blocker, an aldosterone antagonist, a hydralazine and isosorbide dinitrate, a diuretic, and digoxin.

22. The method of claim 12 , wherein the pharmaceutically acceptable salt comprises acetate, hydrochloride or trifluoroacetate salt.

23. A method for reducing the risk of Sengers syndrome in a mammalian subject having decreased expression of AGK compared to a normal control subject, the method comprising: administering to the subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH 2 or a pharmaceutically acceptable salt thereof.

24. The method of claim 23 , wherein the pharmaceutically acceptable salt comprises acetate, hydrochloride or trifluoroacetate salt.

Assignees

• Stealth Biotherapeutics Inc

Inventors

• Carr James
• Dimatteo Michael
• Abbruscato Anthony
• Bjornsson Hans

Classifications

• A61K38/07 Primary

  Tetrapeptides · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/04 Primary

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P9/06

  Antiarrhythmics · CPC title